Research Paper Volume 12, Issue 18 pp 18297—18321

Figure 6. Predictions of the immunotherapy response in GBM patients. The violin plots present the expression of 6 principal immune checkpoint molecules, namely, PDCD1 (PD1), CD274 (PDL1), PDCD1LG2 (PDL2), CTLA4, CD80, and CD86, in scRNA-seq data (A) and bulk RNA-seq data, including the TCGA (B) and CGGA cohorts (C). Subclass mapping analysis was used to predict the likelihood of the clinical response to anti-PD1 and anti-CTLA4 therapy for MC1 and MC2 GBM patients from the TCGA (D) and CGGA (E) cohorts. R represents immunotherapy responders, while noR represents immunotherapy nonresponders. A Bonferroni-corrected P value < 0.05 was considered statistically significant.